Medgenics Inc (NASDAQ:GNMX) – Zacks Investment Research issued their Q1 2017 EPS estimates for shares of Medgenics in a report released on Monday. Zacks Investment Research analyst B. Marckx expects that the firm will post earnings of ($0.28) per share for the quarter. Zacks Investment Research also issued estimates for Medgenics’ Q2 2017 earnings at ($0.30) EPS and Q3 2017 earnings at ($0.29) EPS.
Other equities analysts also recently issued reports about the company. Jefferies Group LLC downgraded Medgenics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $10.00 to $2.50 in a research note on Tuesday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price target (down from $12.00) on shares of Medgenics in a research note on Tuesday, March 21st.
Medgenics (NASDAQ:GNMX) opened at 1.85 on Tuesday. The stock’s market capitalization is $68.65 million. The stock’s 50 day moving average price is $4.50 and its 200-day moving average price is $5.03. Medgenics has a 52 week low of $1.50 and a 52 week high of $6.89.
A number of institutional investors have recently bought and sold shares of the company. Massey Quick & Co. LLC bought a new position in Medgenics during the fourth quarter worth about $126,000. State Street Corp increased its position in Medgenics by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the company’s stock worth $1,789,000 after buying an additional 46,149 shares during the last quarter. Oxford Asset Management bought a new position in Medgenics during the fourth quarter worth about $249,000. Birchview Capital LP bought a new position in Medgenics during the fourth quarter worth about $249,000. Finally, Opaleye Management Inc. bought a new position in Medgenics during the fourth quarter worth about $7,770,000. Institutional investors and hedge funds own 44.69% of the company’s stock.
In other news, major shareholder Philip R. Harper purchased 1,058,531 shares of the firm’s stock in a transaction that occurred on Friday, March 24th. The stock was acquired at an average cost of $1.78 per share, for a total transaction of $1,884,185.18. Following the completion of the purchase, the insider now owns 4,786,682 shares of the company’s stock, valued at $8,520,293.96. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 23.40% of the stock is currently owned by company insiders.
Receive News & Ratings for Medgenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.